Alkermes Plc downgraded by UBS with a new price target
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
UBS downgraded Alkermes Plc from Neutral to Sell and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $42.00 | Neutral → Buy | UBS |
| 5/28/2025 | $45.00 | Buy | Needham |
| 3/13/2025 | $40.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | $21.00 → $38.00 | Sell → Neutral | UBS |
| 2/11/2025 | $40.00 | Buy | Deutsche Bank |
| 11/5/2024 | $25.00 → $36.00 | Hold → Buy | Stifel |
| 6/17/2024 | $34.00 | Buy | TD Cowen |
| 3/19/2024 | $37.00 | Outperform | Robert W. Baird |